The American Society for Radiation Oncology (ASTRO) announced the press program for its 58th Annual Meeting, Sept. 25-28 in Boston. The program includes multiple reports from phase III clinical trials, researchers from leading institutions in the United States and abroad, and examinations of a range of cancer types and patient populations. Researchers will share their findings in a series of briefings held on-site at the Boston Convention & Exhibition Center and webcast to registered press.

September 7, 2016 — Blue Earth Diagnostics announced that the first post-U.S. Food and Drug Administration (FDA) ...

Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the sale of all rights, title and interest to Navidea’s Lymphoseek product. The agreement covers all U.S. Food and Drug Administration (FDA)-approved, pending and future oncology diagnostic indications in North America, subject to certain limitations, as well as certain other related assets. Under the terms of the LOI, Navidea would receive $80 million at closing, with future consideration tied to annual sales of the Lymphoseek product and certain sales-based milestones. Total consideration to Navidea would be capped at $310 million.

Mayfair Diagnostics, a medical imaging clinic in Calgary, Alberta, is revealing its newest medical imaging clinic in Coventry Hills, which is being described as the clinic of the future because of the way it was designed.